Search results
Results from the WOW.Com Content Network
Dapagliflozin, (brand name Forxiga), was approved by the EU in 2012, the first SGLT2 inhibitor approved anywhere. [28] It was approved for use in the United States under the brand name Farxiga in January 2014. [29] Empagliflozin, approved in the United States in August 2014, under the brand name Jardiance by Boehringer Ingelheim. [30]
Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. [ 6 ] [ 7 ] [ 10 ] It is also used to treat adults with heart failure and chronic kidney disease .
CaringBridge allows patients, caregivers, families, and friends to exchange information about a patient's medical condition on an ongoing basis. [3] The websites are designed to become conduits between patients, their families, friends, neighbors, and colleagues. [4]
To lessen the risk of developing ketoacidosis (a serious condition in which the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medicines to recommend they be stopped temporarily before scheduled surgery. Canagliflozin, dapagliflozin ...
Through this free service, specialists and master's-level clinicians offer confidential support and information to people living with dementia, caregivers, families and the public. [4] The Association also has free online tools to help people find answers, local resources and support.
To change this template's initial visibility, the |state= parameter may be used: {{Anti-dementia drugs | state = collapsed}} will show the template collapsed, i.e. hidden apart from its title bar. {{Anti-dementia drugs | state = expanded}} will show the template expanded, i.e. fully visible.
The prevention of dementia involves reducing the number of risk factors for the development of dementia, and is a global health priority needing a global response. [1] [2] Initiatives include the establishment of the International Research Network on Dementia Prevention (IRNDP) [3] which aims to link researchers in this field globally, and the establishment of the Global Dementia Observatory ...
Alzheimer's disease (AD) is a chronic neurodegenerative disease that results in the loss of neurons and synapses in the cerebral cortex and certain subcortical structures, resulting in gross atrophy of the temporal lobe, parietal lobe, and parts of the frontal cortex and cingulate gyrus. [14]